Aeolus Pharmaceuticl (AOLS)

Aeolus Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing novel compounds for biodefense and for therapeutic use in fibrosis, oncology, infectious diseases, and central nervous system disorders. The company’s work centers on catalytic antioxidant compounds intended as medical countermeasures against nuclear, radiological, and chemical threats, as well as potential treatments for respiratory, neurological, and cancer-related conditions. Its lead candidate, AEOL 10150, has completed two Phase I clinical trials and is being developed for the pulmonary sub-syndrome of acute radiation syndrome and for exposure to chemical vesicants and nerve agents. Aeolus is also advancing AEOL 11207 as a potential treatment for Parkinson’s disease. The company was founded in 1994 and is based in Mission Viejo, California. Aeolus Pharmaceuticals common stock trades on OTC Markets under the symbol AOLS.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.